Injective Labs

Injective Labs is a research and development company focused on creating unmatched Web3 infrastructure and finance solutions. It is one of the core contributors to Injective. Injective Labs operates through several subsidiaries, including Injective Protocol, Helix, and Mito. Injective Protocol is the first sector-specific blockchain built specifically for finance, offering smart contracts and high interoperability with prominent Layer 1 blockchains. Helix is a decentralized orderbook crypto exchange for trading crypto assets and derivatives, providing zero gas fees and an intuitive user interface. Mito is a next-generation DeFi protocol combining strategy vaults for passive yield generation and a one-click token launchpad. The team at Injective Labs comprises distinguished engineers, traders, and operators with extensive experience across leading industries. The leadership team includes CEO Eric Chen, CTO Albert Chon, Head of Business Development Mirza Uddin, and Head of Engineering David Josse. The company is headquartered in New York, NY, and operates globally, with a team spanning multiple countries and languages. Injective Labs is committed to creating a more free and inclusive financial paradigm through decentralization, with a focus on transparency, collaboration, and pioneering efforts in the Web3 space.

Focus on decentralized finance and blockchain technology projects, Active involvement in the Web3 ecosystem, Commitment to creating a more free and inclusive financial paradigm through decentralization